Alternatives to Bulgaria – Medical consumables – „Доставка на медицински изделия/консумативи за нуждите на Клинична лаборатория при УМБАЛСМ" Н.И.Пирогов" ЕАД

Bulgaria – Pharmaceutical products – Доставка на лекарствени продукти за Клиника по онкология, включени в приложение № 2 от списъка на НЗОК за 2026 / 2027 г.

Bulgaria – Medical equipments – ДОСТАВКА НА МЕДИЦИНСКА АПАРАТУРА/ОБОРУДВАНЕ ЧАСТ VI ЗА НУЖДИТЕ НА „МБАЛ - ХАСКОВО“ АД

Expected Impact: The action under this topic is expected to achieve the following impacts: Accelerate EU access to more cost-effective interventions in an increasingly ageing population by identifying personalised treatment approaches for elderly-onset immune diseases. Decrease disease risk later in life by defining specific prevention strategies based on ageing biomarkers and risk factors. Halt age-associated disease exacerbation by the identification of predictive and digital biomarkers that can stratify patients for early intervention. Improve quality of life for healthy individuals and patients by preventing further health decline, avoiding escalating care costs, and properly stratifying individuals earlier in the diagnostic pathway. Accelerate adoption of innovative diagnostic, preventative, and therapeutic strategies, strengthening the EU’s position as a healthcare innovator. Evaluate digital biomarker as potential regulatory endpoints in the ultimate goal to develop medicines for ‘healthy ageing’. Integrate fragmented research efforts by bringing together health industry sectors and stakeholders to develop clinical and multi-omics data integration capabilities. Enable new…

Expected Impact: The action under this topic is expected to achieve the following impacts: Faster and more informed decision-making through the use of an AI-driven NAM (AI Foundation Toxicology Model) and increased efficiency through rapid processing of vast amounts of data [1] . Increased consistency and standardisation in a NAM-based approach, specifically an AI model, used by industry in the efficient development, testing and production of safe and effective innovative health technologies, improving industrial competitiveness. Regulatory adoption of a NAM-enabled second species waiver model (AI Foundation Toxicology Model) and weight-of-evidence framework, in line with recommendations and more consistent global decision-making on waiving second species testing. Reduction in animal use, accelerated timelines and lower costs, enhancing the competitiveness of the European health industry through economical and ethical benefits. Improved public health as patients will benefit from safe and effective medicines developed faster using validated NAMs. The action is expected to contribute to the EU Directive (2010/63/EU) [2] on the protection of animals used for scientific purposes and…

Expected Impact: The action under this topic is expected to achieve the following impacts and contribute to the following EU policies/initiatives: deliver innovative, early technology solutions that contribute to addressing strategic unmet public health needs across multiple therapy areas to improve prevention, early diagnosis, and treatment; leverage the unique network and scale of IHI JU members to create a pipeline to support innovative startups in the health industry, fully integrated into European initiatives in support of start-ups and entrepreneurship; drive early cross-sector health R&D and innovation to strengthen the European healthcare industry’s global competitiveness, contributing to the EU Industrial Strategy and Pharmaceutical Strategy objectives; create a sustainable network of European healthcare incubators to guide and support highly talented and innovative early-stage companies; harness digital health and data-sharing technologies (e.g., AI and big data) to enable interoperable health solutions, contributing to the European Health Data Space (EHDS) and improved evidence based care;- the action should generate a portfolio of early‑stage companies that have…

Expected Outcome: This action aims to establish European leadership in neutral-atom quantum simulation and digital quantum computing by delivering: Fully programmable industry-ready quantum simulators based on 10.000 neutral atoms in a scalable architecture, accessible via cloud platforms, and with the possibility of integrating them into high-performance computing environments. Fully programmable platform for neutral-atom quantum computing capable of both analogue quantum operations and gate-based computing with 1.000 physical qubits and a clear path to further scalability to 10.000 physical qubits. Coherence time of the order of hundreds of interaction times and infidelity of operations below 1%. Demonstration of quantum simulation and/or computing operating beyond classical computability, validated through benchmarking with classical methods. New real-world applications across science and industry (at least two) (e.g: in the energy and health sectors) The software stack for these applications, including enhanced software for verification, algorithm implementation, and user programming interfaces. Demonstration of the full quantum stack – including quantum control, electronic…

Expected Outcome: Project results are expected to contribute to all of the following expected outcomes: Implementation of the NWRSA methodology for secondary rural roads; Innovative and effective enforcement strategies, incentive mechanisms and measures raising risk awareness for fostering safer behaviour; Prevention strategies for reducing road fatalities and serious road traffic injuries on rural roads along with the respective implementation guidelines and policy measures tailored to the responsible stakeholders (regional authorities, police, healthcare professionals, national governments, etc.); GIS-based application to assist local and regional authorities in identifying and mapping the impact of extreme weather phenomena and other natural disasters (such as floods, fires, storms, heavy snowfall etc.) on the safety and resilience of the road network in their jurisdiction. Scope: With more than 50% of all EU road fatalities occurring in rural areas along with evidence suggesting that crashes and crash-related fatalities in rural roads vary from those in urban roads or motorways, it is imperative to understand and mitigate the safety risks in rural roads in view of the EU’s…

The focus of this notice of funding opportunity (NOFO) is to produce insights into disease detection and prevention strategies, burden, severity, diagnostics, treatment, and outcomes of infectious diseases in international travelers. Timely surveillance and sentinel detection are essential for collecting actionable data. The research should:Address public health questions that improve the speed of outbreak detection.Help develop guidelines and recommendations to improve patient care.Enhance understanding of the natural history of disease.Optimize genomic surveillance as well as diagnostic and treatment strategies.Advance the global health security of the United States.This NOFO will have two components:Component A – Clinic-based sentinel network.Component B – Sentinel detection in international transportation hubs.You may apply for Component A, B, or both. If your application for both Component A and B is ranked top, Component B will be awarded.

NHS Essex Integrated Care Board is undertaking a Competitive Process under the Health Care Services (Provider Selection Regime) Regulations 2023 for the award of a General Medical Services (GMS) contract for Tollgate Practice, Stanway, Colchester. The Authority seeks a suitably qualified provider to deliver primary medical services to a registered patient population of approximately 10,206 patients. Services will be provided under a nationally prescribed GMS contract from the existing practice premises and will include the delivery of core primary medical services, management of the registered patient list, clinical governance, safeguarding, information governance and integration with local health and care services. This procurement is being undertaken to secure the long-term provision of stable, resilient and high-quality primary medical services for the local population. Due to the fixed practice location, established patient list and requirement for uninterrupted service delivery, bidders must demonstrate the ability to mobilise and maintain an appropriately qualified workforce and robust governance arrangements from contract commencement. The contract will be awarded following evaluation against the key criteria set out in the Health Care Services (Provider Selection Regime) Regulations 2023. The estimated contract value is £21,896,491.60, calculated using a notional 20-year term for valuation purposes only. The contract itself is a perpetual GMS contract and is not time limited. Additional information: To express interest and participate in the tender, please register and apply via Atamis e-sourcing portal https://health-family.force.com/s/Welcome. Should Tenderers have any queries, or having problems using the portal, they should contact Helpdesk at: Phone: 0800 9956035 E-mail: support-health@atamis.co.uk

Sweden – CT scanners – Datortomografer

France – Radiotherapy devices and supplies – FOURNITURE D’EQUIPEMENTS ET LOGICIELS DE RADIOTHERAPIE ET PRESTATIONS ASSOCIEES

Spain – Medical consumables – Suministro de equipos de cobertura quirúrgica desechable, material auxiliar y elementos fungibles asociados para la Osi Bilbao Basurto, y puesta a disposición de un modelo de gestión logística automat